[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP21036194A - Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos - Google Patents

Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos

Info

Publication number
ECSP21036194A
ECSP21036194A ECSENADI202136194A ECDI202136194A ECSP21036194A EC SP21036194 A ECSP21036194 A EC SP21036194A EC SENADI202136194 A ECSENADI202136194 A EC SENADI202136194A EC DI202136194 A ECDI202136194 A EC DI202136194A EC SP21036194 A ECSP21036194 A EC SP21036194A
Authority
EC
Ecuador
Prior art keywords
pcsk9
treatment
inhibitors
metabolic disorders
proprotein convertase
Prior art date
Application number
ECSENADI202136194A
Other languages
English (en)
Inventor
Tajesh Jayprakash Patel
Lauren Gilchrist Monovich
Brian Addison Dechristopher
Philipp Grosche
Carina Cristina Sanchez
Rui Zheng
Alec Nathanson Flyer
Liansheng Su
Karin Briner
Justin Yik Ching Mao
Andrei Alexandrovich Golosov
Eugene Yuejin Liu
Lihua Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP21036194A publication Critical patent/ECSP21036194A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a inhibidores de PCSK9 de utilidad en el tratamiento del metabolismo de los lípidos del colesterol y otras enfermedades en las que PCSK9 interviene, que tienen la fórmula (I): (I), o una sal, hidrato, solvato, profármaco, estereoisómero, N-óxido o tautómero farmacéuticamente aceptable de los mismos, en donde R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, y X3 están descriptos en la presente.
ECSENADI202136194A 2018-11-27 2021-05-21 Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos ECSP21036194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862772030P 2018-11-27 2018-11-27
US201962924828P 2019-10-23 2019-10-23

Publications (1)

Publication Number Publication Date
ECSP21036194A true ECSP21036194A (es) 2021-06-30

Family

ID=68808460

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202136194A ECSP21036194A (es) 2018-11-27 2021-05-21 Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos

Country Status (24)

Country Link
US (2) US11026993B2 (es)
EP (1) EP3887365A1 (es)
JP (1) JP7577656B2 (es)
KR (1) KR20210096154A (es)
CN (1) CN113166114B (es)
AU (1) AU2019387294B2 (es)
BR (1) BR112021009857A2 (es)
CA (1) CA3115960A1 (es)
CL (1) CL2021001365A1 (es)
CO (1) CO2021006895A2 (es)
CR (1) CR20210267A (es)
CU (1) CU20210043A7 (es)
DO (1) DOP2021000100A (es)
EC (1) ECSP21036194A (es)
IL (1) IL283374A (es)
JO (1) JOP20210120A1 (es)
MA (1) MA54284A (es)
MX (1) MX2021006069A (es)
PE (1) PE20211658A1 (es)
PH (1) PH12021551049A1 (es)
SG (1) SG11202103807WA (es)
TW (1) TW202038990A (es)
UY (1) UY38485A (es)
WO (1) WO2020110009A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11882610B2 (en) * 2020-08-13 2024-01-23 Qualcomm Incorporated Establishing connections using multiple subscriber identity modules via a single communication link
CN114163343A (zh) * 2021-12-10 2022-03-11 许昌学院 含氟氨基酸及衍生物含氟多肽的制备方法以及应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
JP3262329B2 (ja) 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス 糖尿病治療に有用なｇｌｐ―１アナログ
US5155100A (en) 1991-05-01 1992-10-13 Ciba-Geigy Corporation Phosphono/biaryl substituted dipeptide derivatives
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
IT1291776B1 (it) 1997-02-07 1999-01-21 Menarini Ricerche Spa Composti monociclici a quattro residui bifunzionali, aventi azione nk-2 antagonista
IT1304888B1 (it) 1998-08-05 2001-04-05 Menarini Ricerche Spa Composti monociclici ad azione nk-2 antagonista e formulazioni che licontengono
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
IT1307809B1 (it) * 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
KR20020089437A (ko) 2000-04-12 2002-11-29 노파르티스 아게 유기 화합물의 배합
EP1297826A1 (en) 2001-09-27 2003-04-02 Menarini Ricerche S.p.A. Nasal pharmaceutical compositions containing a NK-2 antagonist
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
AU2003232941A1 (en) 2002-06-07 2003-12-22 Glaxo Group Limited N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them
US7732603B2 (en) 2002-08-07 2010-06-08 Novartis Ag Organic compounds as agents for the treatment of aldosterone mediated conditions
ATE398124T1 (de) 2002-11-18 2008-07-15 Novartis Pharma Gmbh Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron
CN1795193B (zh) 2003-05-20 2010-08-18 诺瓦提斯公司 用作过氧化物酶体增殖物激活受体的配体的n-酰基含氮杂环化合物
CN1968930A (zh) 2004-05-28 2007-05-23 斯皮德尔实验股份公司 作为芳化酶抑制剂的双环含氮杂环
BRPI0510412A (pt) 2004-05-28 2007-10-23 Speedel Experimenta Ag compostos orgánicos
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2006005726A2 (en) 2004-07-09 2006-01-19 Speedel Experimenta Ag Heterocyclic compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
KR101456721B1 (ko) 2006-03-31 2014-10-31 노파르티스 아게 신규 화합물
CN101415803B (zh) 2006-04-04 2012-10-24 大阳日酸株式会社 甲烷分离方法、甲烷分离装置以及甲烷利用系统
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
US20090264420A1 (en) 2006-08-25 2009-10-22 Gary Michael Ksander Organic compounds
CA2673119A1 (en) 2006-12-18 2008-06-26 Novartis Ag 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
KR20090094374A (ko) 2006-12-18 2009-09-04 노파르티스 아게 1-치환된 이미다졸 유도체 및 알도스테론 신타제 억제제로서의 그의 용도
US8436035B2 (en) 2006-12-18 2013-05-07 Novartis Ag Organic compounds
EP2134720B1 (en) 2007-03-29 2010-10-13 Novartis AG Heterocyclic spiro-compounds
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
EP2200975A1 (en) 2007-09-07 2010-06-30 Theravance, Inc. Dual-acting antihypertensive agents
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US8673270B2 (en) 2008-10-23 2014-03-18 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
CA2761859A1 (en) 2009-05-15 2010-11-18 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
EA019511B1 (ru) 2009-05-28 2014-04-30 Новартис Аг Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
AU2010313068B2 (en) * 2009-10-01 2014-04-10 Cadila Healthcare Limited Compounds for the treatment of dyslipidemia and related diseases
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2504352B1 (en) 2009-11-23 2018-11-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
KR101892500B1 (ko) 2010-12-15 2018-08-28 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 억제제
MX342212B (es) 2011-02-17 2016-09-20 Theravance Inc Inhibidores de neprilisina.
JP5959074B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
ES2642883T3 (es) 2011-05-31 2017-11-20 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
ES2632600T3 (es) 2012-06-08 2017-09-14 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
DE102012014480A1 (de) 2012-07-21 2014-01-23 Daimler Ag Aufbau eines Innendekors
RS55797B1 (sr) 2012-08-08 2017-08-31 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
WO2014029022A1 (en) 2012-08-21 2014-02-27 Abdelmalik Slassi Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
AU2014216424B2 (en) 2013-02-14 2016-05-05 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors
LT2964616T (lt) 2013-03-05 2017-07-25 Theravance Biopharma R&D Ip, Llc Neprilizino inhibitoriai
CA2904662A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
WO2015116786A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
WO2015116760A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
TW201823222A (zh) 2016-12-23 2018-07-01 財團法人生物技術開發中心 化合物、醫藥組成物及其用途

Also Published As

Publication number Publication date
KR20210096154A (ko) 2021-08-04
CR20210267A (es) 2021-08-16
CN113166114A (zh) 2021-07-23
TW202038990A (zh) 2020-11-01
CO2021006895A2 (es) 2021-06-10
JP7577656B2 (ja) 2024-11-05
SG11202103807WA (en) 2021-06-29
AU2019387294B2 (en) 2022-09-08
US11026993B2 (en) 2021-06-08
CU20210043A7 (es) 2022-01-13
MA54284A (fr) 2022-03-02
US11813306B2 (en) 2023-11-14
WO2020110009A1 (en) 2020-06-04
EP3887365A1 (en) 2021-10-06
JOP20210120A1 (ar) 2023-01-30
AU2019387294A1 (en) 2021-05-13
CN113166114B (zh) 2025-01-03
UY38485A (es) 2020-06-30
CL2021001365A1 (es) 2022-01-14
MX2021006069A (es) 2021-07-06
JP2022507957A (ja) 2022-01-18
PE20211658A1 (es) 2021-08-24
DOP2021000100A (es) 2021-06-30
PH12021551049A1 (en) 2021-12-06
BR112021009857A2 (pt) 2021-08-17
IL283374A (en) 2021-07-29
CA3115960A1 (en) 2020-06-04
US20210252103A1 (en) 2021-08-19
US20200164024A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
DOP2018000150A (es) Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
NI201900088A (es) Dendrímeros terapéuticos
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CY1123532T1 (el) Αναστολεις του gingipain λυσινης
ECSP21036194A (es) Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos
DOP2017000123A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
EA201890616A1 (ru) Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
AR106352A1 (es) Compuestos de aminotioléster o las sales farmacéuticamente aceptables del mismo, para usar en el tratamiento del cáncer
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano